Navin Pinto, MD

Publications

• Ronsley R, Huang W, Rohlf E, Seidel K, Brown C, Beebe A, Rawlings-Rhea SD, Lindgren C, Sad T, Crotty EE, Leary SES, Thomsen A, Beckstrom AR, Holtzclaw SL, Hoeppner C, Hurst D, MacQuivey M, Goldstein HE, Browd SR, Hauptman JS, Lee A, Ojemann JG, Wright JN, Albert CM, Pinto N, Gustafson JA, Ho O, Pattabhi S, Summers C, Annesley C, Wendler JN, Gust J, Gardner RA, Park JR, Jensen MC, Vitanza NA. Intracerebroventricular B7-H3-targeting CAR T cells for non-pontine DMG and recurrent/refractory pediatric CNS tumors: a phase 1 trial. Neuro Oncol. 2026 Jul 25. [Epub ahead of print] PubMed PMID: 42503899
• Sokol E, Naranjo A, Chen L, Mody R, DuBois SG, Bagatell R, Pinto N. Long-Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2026 Sep;73(9):e70504. PubMed PMID: 42487540
• Pinto N, Künkele A, Albert CM, Taylor MR, Ullom HB, Vitanza NA, Wilson AL, Cole BL, Yeung CCS, Wright JH, Huang W, Wendler J, Seidel K, Brown C, Gustafson J, Rawlings-Rhea SD, Beebe A, Mgebroff S, Gardner RA, Jensen MC, Park JR. The First-in-Human ENCIT01 Trial Comparing Second- versus Third-Generation L1CAM-specific CAR T Cells in Patients with Primary Refractory or Relapsed Neuroblastoma. Clin Cancer Res. 2026 Sep 15;32(18):4062-4074. PubMed PMID: 42312971
• Bair SM, Pinto N, Roth A, Verneris M, Haverkos B, Nicklawsky A, Ohm A, Jordan K, Murphy LA, Marians R, Mallo R, Orentas R, Adams C, Kamdar M, Fry T. Feasibility and Safety of a Novel CD19-Directed CAR T-Cell Therapy in Patients with R/R B-Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2026 Jun 3. [Epub ahead of print] PubMed PMID: 42242517
• Kang W, Lazo de la Vega L, Comeau H, Agastra E, Maese LD, Kim A, Sukharevsky E, Ceca E, Corson L, White J, Weiser DA, Applebaum MA, Colace SI, Chen M, Johnson JA, Volchenboum S, Pinto NR, Church AJ, Janeway KA. Introducing iCatalog as a clinical decision support tool for collaborative pediatric precision oncology studies. Commun Med (Lond). 2026 Jan 23;6(1):88. PubMed PMID: 41571967
• Taylor MR, Anderson JR, Park JR, Irwin MS, Applebaum MA, Pinto NR, Streby K, Federico SM, Rosswog C, Ohira M, Kao PC, London WB, Cash T. Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) Project. Pediatr Blood Cancer. 2025 Nov;72(11):e31968. PubMed PMID: 40879138
• Balis F, Green DM, Armstrong A, Aye J, Benedetti D, Brown B, Brown E, Cook S, Desai A, Dhillon J, Fair D, Geynisman DM, Hiniker S, Horst K, Jasty-Rao R, Just M, Kieran K, Lin C, MacEwan I, Martinez-Agosto J, Mullen E, Murphy ES, Pinto N, Ranalli M, Rhee D, Rokitka D, Walz A, Wickiser J, Yoon J, Zapala M, Montgomery S, Sliker B. Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Aug;23(8):319-342. PubMed PMID: 40763792
• Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, Acharya PT, Pawel B, Erbe AK, Shahi A, Zaborek J, Kennedy E, Asgharzadeh S, Villablanca JG, Pinto N, Weiss BD, Mosse YP, Desai AV, Macy ME, Granger M, Vo KT, Sondel PM, Matthay KK, Park JR, Goldsmith KC. Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025 Aug;43(22):2490-2501. PubMed PMID: 40549985
• Gust J, Cole BL, Ronsley R, Wilson AL, Seidel K, Wendler J, Pattabhi S, Brown C, Rawlings-Rhea SD, Shtanukhina N, Browd SR, Hauptman JS, Lee A, Ojemann JG, Crotty EE, Leary SES, Perez FA, Wright JN, Albert CM, Pinto N, Gardner RA, Vitanza NA, Jensen MC, Park JR. Locoregional infusion of EGFR806-CAR T cells for recurrent or refractory pediatric CNS tumors: Results of the completed BrainChild02 phase 1 clinical trial. Neuro Oncol. 2025 Sep 17;27(8):2170-2181. PubMed PMID: 40070357
• Vitanza NA, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea SD, Beam M, Steinmetzer L, Wilson AL, Brown C, Beebe A, Lindgren C, Gustafson JA, Wein A, Holtzclaw S, Hoeppner C, Goldstein HE, Browd SR, Hauptman JS, Lee A, Ojemann JG, Crotty EE, Leary SES, Perez FA, Wright JN, Alonso MM, Dun MD, Foster JB, Hurst D, Kong A, Thomsen A, Orentas RJ, Albert CM, Pinto N, Annesley C, Gardner RA, Ho O, Pattabhi S, Gust J, Wendler JP, Park JR, Jensen MC. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat Med. 2025 Mar;31(3):861-868. PubMed PMID: 39775044
• Pinto N, Albert CM, Taylor MR, Ullom HB, Wilson AL, Huang W, Wendler J, Pattabhi S, Seidel K, Brown C, Gustafson JA, Rawlings-Rhea SD, Cheeney SHE, Burleigh K, Gustafson HH, Orentas RJ, Vitanza NA, Gardner RA, Jensen MC, Park JR. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors. J Clin Oncol. 2024 Sep 10;:JCO2302229. [Epub ahead of print] PubMed PMID: 39255444
• Vitanza NA, Choe M, Brown C, Beebe A, Kong A, Rogers L, Jacob S, Mano E, Abuan K, Mgebroff S, Lindgren C, Gustafson JA, Wilson AL, Noll A, Ronsley R, Crotty EE, Leary SES, Foster JB, Pinto N, Gust J, Gardner RA, Park JR, Jensen MC. Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities. J Hematol Oncol Pharm. 2024 Aug;14(4):148-154. PubMed PMID: 39238483
• Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai AV, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024 Aug;22(6):413-433. PubMed PMID: 39151455
• Navarro SL, Pinto N, Hawkins DS, Park JR, Dilmaghani S, Rimorin C, Wurscher M, McCune JS. Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with 4hydroxycyclophosphamide formation in children with Cancer. Cancer Chemother Pharmacol. 2024 Oct;94(4):627-633. PubMed PMID: 39080017
• Goldsmith KC, Park JR, Kayser K, Malvar J, Chi YY, Groshen SG, Villablanca JG, Krytska K, Lai LM, Acharya PT, Goodarzian F, Pawel B, Shimada H, Ghazarian S, States L, Marshall L, Chesler L, Granger M, Desai AV, Mody R, Morgenstern DA, Shusterman S, Macy ME, Pinto N, Schleiermacher G, Vo K, Thurm HC, Chen J, Liyanage M, Peltz G, Matthay KK, Berko ER, Maris JM, Marachelian A, Mossé YP. Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results. Nat Med. 2023 May;29(5):1092-1102. PubMed PMID: 37012551
• Marinoff AE, Spurr LF, Fong C, Li YY, Forrest SJ, Ward A, Doan D, Corson L, Mauguen A, Pinto N, Maese L, Colace S, Macy ME, Kim A, Sabnis AJ, Applebaum MA, Laetsch TW, Glade-Bender J, Weiser DA, Anderson M, Crompton BD, Meyers P, Zehir A, MacConaill L, Lindeman N, Nowak JA, Ladanyi M, Church AJ, Cherniack AD, Shukla N, Janeway KA. Clinical Targeted Next-Generation Panel Sequencing Reveals MYC Amplification Is a Poor Prognostic Factor in Osteosarcoma. JCO Precis Oncol. 2023 Mar;7:e2200334. PubMed PMID: 36996377
• Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S. Impact of Genomic and Clinical Factors on Outcome of Children =18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report. Clin Cancer Res. 2023 Apr 14;29(8):1546-1556. PubMed PMID: 36749880
• Vitanza NA, Ronsley R, Choe M, Henson C, Breedt M, Barrios-Anderson A, Wein A, Brown C, Beebe A, Kong A, Kirkey D, Lee BM, Leary SES, Crotty EE, Hoeppner C, Holtzclaw S, Wilson AL, Gustafson JA, Foster JB, Iliff JJ, Goldstein HE, Browd SR, Lee A, Ojemann JG, Pinto N, Gust J, Gardner RA, Jensen MC, Hauptman JS, Park JR. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. Neoplasia. 2023 Feb;36:100870. PubMed PMID: 36599192
• Vitanza NA, Wilson AL, Huang W, Seidel K, Brown C, Gustafson JA, Yokoyama JK, Johnson AJ, Baxter BA, Koning RW, Reid AN, Meechan M, Biery MC, Myers C, Rawlings-Rhea SD, Albert CM, Browd SR, Hauptman JS, Lee A, Ojemann JG, Berens ME, Dun MD, Foster JB, Crotty EE, Leary SES, Cole BL, Perez FA, Wright JN, Orentas RJ, Chour T, Newell EW, Whiteaker JR, Zhao L, Paulovich AG, Pinto N, Gust J, Gardner RA, Jensen MC, Park JR. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety. Cancer Discov. 2023 Jan 9;13(1):114-131. PubMed PMID: 36259971
• Lerman BJ, Li Y, Carlowicz C, Granger M, Cash T, Sadanand A, Somers K, Ranavaya A, Weiss BD, Choe M, Foster JH, Pinto N, Morgenstern DA, Rafael MS, Streby KA, Zeno RN, Mody R, Yazdani S, Desai AV, Macy ME, Shusterman S, Federico SM, Bagatell R. Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor. J Clin Oncol. 2023 Jan 20;41(3):508-516. PubMed PMID: 36206505

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234